The meta- analysis showed a significant increase in plasma adiponectin levels following statin therapy .
Although statins are known to increase the risk for new onset diabetes mellitus , our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression
BACKGROUND AND AIMS The effect of statin therapy on plasma adiponectin levels has not been conclusively studied .
Therefore , we aim ed to evaluate this effect through a systematic review and meta- analysis of available r and omized controlled trials ( RCTs ) .
Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus.
OBJECTIVE Pravastatin has been reported to elevate circulating adiponectin levels in patients with various insulin resistant state , hypertension , coronary artery disease , and hypercholesterolemia . This study aim ed to evaluate whether pravastatin increase serum total and high molecular weight adiponectin levels and improve insulin sensitivity in female patients with type 2 diabetes mellitus and hypercholesterolemia . PATIENTS AND DESIGN This study was design ed as a multicenter , double-blind , placebo-controlled , factorial r and omized trial ( placebo and pravastatin at 20 or 40 mg per day ) . A total of 73 female patients with type 2 diabetes and hypercholesterolemia were enrolled . Changes in total and high molecular weight ( HMW ) serum adiponectin levels , the ratio of HMW adiponectin to total adiponectin , insulin sensitivity measured by homeostasis model assessment of insulin resistance ( HOMA-IR ) and lipid profiles were evaluated after 16 weeks in each group . RESULTS Total cholesterol and low-density lipoprotein ( LDL ) cholesterol levels were significantly reduced after 16 weeks in the pravastatin 20 mg and 40 mg treatment groups compared with the placebo group ( P = 0.008 and P = 0.004 , respectively ) . However , there were no significant differences between the 20 mg and 40 mg pravastatin treatment groups in terms of total adiponectin and HMW adiponectin serum levels , as well as insulin sensitivity ( P = 0.348 and P = 0.991 ) . CONCLUSIONS In female patients with type 2 diabetes and hypercholesterolemia , 16 weeks pravastatin therapy did not affect on serum total adiponectin or HMW adiponectin levels
The meta- analysis showed a significant increase in plasma adiponectin levels following statin therapy .
Although statins are known to increase the risk for new onset diabetes mellitus , our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression
BACKGROUND AND AIMS The effect of statin therapy on plasma adiponectin levels has not been conclusively studied .
Therefore , we aim ed to evaluate this effect through a systematic review and meta- analysis of available r and omized controlled trials ( RCTs ) .